Luca Gerosa

National University of Singapore — Singapore

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index2.2kcitations43works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(15), Computational Drug Discovery Methods(10), RNA modifications and cancer(8), Gene Regulatory Network Analysis(6), Microbial Metabolic Engineering and Bioproduction(6)

Publications43 total

Data from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025· 1 citedOpen Access
Supplementary Figure S2 from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025Open Access
Supplementary Figure S3 from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025Open Access
Supplementary Figure S1 from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025Open Access
Supplementary Table S1 from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025Open Access
Supplementary Figure S4 from RIT1<sup>M90I</sup> Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
2025Open Access
Abstract LT03: Cell confinement by micropatterning induces phenotypic changes in cancer-associated fibroblasts
Cancer Research·2025
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
Cancer Research·2025
Abstract 6849: RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy
Cancer Research·2025· 1 cited
Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Nature Communications·2025· 13 citedOpen Access
CDK2 activity crosstalk on the ERK kinase translocation reporter can be resolved computationally
Cell Systems·2025· 4 citedOpen Access
The impact of bicuspid valve morphology on the selection of transcatheter aortic valve implantation devices: an <i>in silico</i> study
European Heart Journal - Imaging Methods and Practice·2025· 2 citedOpen Access
Belvarafenib Inhibits the Growth of <i>RAS</i>-Mutant Acute Myeloid Leukemia Cell Lines <i>in Vitro</i> and Drives Adaptive Resistance <i>In Vivo</i>
Blood·2024· 1 citedOpen Access
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma
Cancers·2024Open Access
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma
2024Open Access
RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy
Research Square (Research Square)·2024· 1 citedOpen Access
Abstract A012: Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib
Cancer Research·2024
A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
2024Open Access
Efficacy of Belvarafenib with and without Cobimetinib in Preclinical Models of Ras Pathway-Mutant AML
Blood·2023· 2 cited
Abstract PR02: Factors modulating RAF dimerization downstream of RAS – A mechanistic overview
Molecular Cancer Research·2023
page 1 of 3Next →

Frequent Co-authors

Peter K. Sorger(12), Thomas Hunsaker(12), Mark Merchant(11), Nicole M. Sodir(10), Danilo Maddalo(10), Ashley V. DiMarco(9), Anthony Lima(9), Julie Weng(9), Charles Havnar(9), Kai Barck(9), Klára Tótpál(9), Oded Foreman(9), Uwe Sauer(8), Jennifer A. Lacap(8), Mirunalini Ravichandran(8), Jeff Lau(8), Pablo Saenz-Lopez Larrocha(8), Eva Lin(8), Wennie Chen(8), Yang Xiao(7)